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Abstract
Arthritis causes disability due to pain and inflammation in joints. There are many forms of arthritis, one of which is
osteoarthritis whose prevalence increases with age. It occurs in various joints including hip, knee and hand with
knee osteoarthritis being more prevalent. There is no cure for it. The management strategies include exercise,
glucosamine plus chondroitin sulfate and NSAIDs. In vitro and animal studies provide a rationale for the use of
antioxidant supplements for its management. This review assesses the reality of the benefits of antioxidant
supplements in the management of knee osteoarthritis. Several difficulties were encountered in examining this
issue: poorly conducted studies, a lack of uniformity in disease definition and diagnosis, and muddling of
conclusions from attempts to isolate the efficacious molecules. The antioxidant supplements with most evidence
for benefit for pain relief and function in knee osteoarthritis were based on curcumin and avocado-soya bean
unsaponifiables. Boswellia and some herbs used in Ayurvedic and Chinese medicine may also be useful. The
benefits of cuisines with the appropriate antioxidants should be assessed because they may be more economical
and easier to incorporate into the lifestyle.
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Current knowledge
Arthritis may have originated before man itself since it
also afflicts other primates [1]. The disease causes dis-
ability due to pain and inflammation in joints. There are
many different types of arthritis of which rheumatoid
arthritis and osteoarthritis (OA) are the most common.
Rheumatoid arthritis is an autoimmune disease that af-
fects mainly small joints such as those in the fingers of
the hand. OA affects large joints such as hips and knees
and also those in the hands. OA is a leading cause of
disability with an unknown cause or cure. The global
age standardised prevalence of OA in the knee and hip
has recently been reported to be 3.8 and 0.85 %, respect-
ively [2]. Worldwide estimates indicate that 9.6 % of
men and 18 % of women ≥60 years have symptomatic
OA (http://www.who.int/chp/topics/rheumatic/en/).
Other risk factors of knee OA include trauma such as
torn meniscus, occupation, exercise, gender (more com-
mon in females), ethnicity, genetics, obesity, diet and
bone density [2]. Since OA normally progresses with
age, its economic burden may increase with the aging
human population in the coming decades. This review
will focus on knee OA which is more common. The
knee joints are the largest and being synovial joints,
they provide a very high degree of mobility. A knee
joint provides two articulations - one between tibia and
femur and the other between patella and femur [3, 4].
The joints allow for flexion, extension and a limited
degree of rotation. It contains a bone-cartilage interface
and a synovial body. The synovial body contains the
fluid whose composition and viscosity are key to the
knee operation. The bone-cartilage interface is a com-
plex functional unit and biocomposite at the centre of
joint function in which the individual components
interact cooperatively and synergistically. Due to this
intimate contact between bone and cartilage, any
changes in either tissue will influence the other compo-
nent. Its role in knee OA is discussed in the next
section.
Pathophysiology of knee OA
The suggested causes for the development of OA in-
clude genetic predisposition, aging, obesity, trauma, and
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other systemic diseases [5]. Irrespective of the etiology, a
number of processes that occur in the initial stages may
involve cellular and ultrastructural changes which grad-
ually accompany the phenotypic image of OA. During
OA there is a loss of cartilage, the subchondral bone be-
comes thicker, the subchondral trabecular bone mass de-
creases and new osteophytes are formed [3]. These
changes may lead to the development of bone cysts and
lesions in the bone marrow. Subsequently, the cartilage
layer may be calficified and cracks may occur in it. The
chondrocytes, which are normally quiescent, may also
actively proliferate and form clusters. An early-stage in-
crease in the remodelling and bone loss followed by a
slow remodelling and subchondral densification are hall-
marks of OA pathogenesis [6].
It is commonly stated that the articular cartilage pro-
tects the bone to prevent any damage during motion,
however, the articular cartilage, subchondral plate and
trabecular bone are a biologically and functionally insep-
arable osteochondral unit which absorbs and distributes
loads across the joint [7, 8]. The osteochondral plate
consists of the following: a thin layer of cortical bone
(also called the subchondral plate), a calcified layer of
cartilage, adjacent articular cartilage and the tidemark.
The subchondral plate is a highly vascular cortical bone.
The entire osteochondral plate should be viewed as an
exchange area between bone and cartilage through
which the bone supplies the cartilage with nutrients and
oxygen. Due to this intimate contact between bone and
cartilage, any changes in either tissue will influence the
other component. The distance between the two bones
is important because a decrease in this distance may in-
crease friction during motion. The muscles and the joint
are vascularized and innervated. Thus, changes in the el-
ements in the supplied blood may also influence the
properties of the joint. This also means that signals from
the nerves may lead to a neuropathic pain in the joint [3].
During OA there is a loss of cartilage, the subchondral
bone becomes thicker, the subchondral trabecular bone
mass decreases and new osteophytes are formed [3]. It
has been shown that the subchondral bone sclerosis is
characterized by a trabecular thickening and a decrease
in calcium binding to the collagen fibers. This abnormal
mineralization is due to the overproduction of the
homotrimeric alpha1 form of type I collagen by osteo-
blasts. This (α1)3 type I collagen has a lower affinity for
calcium than the (α1)2 α2 type I collagen [7, 8]. This is
consistent with a recent study using Raman spectros-
copy which concluded that the chemical compositions
and collagen quality were different between subchondral
bone in the advanced OA and the non-OA distal femur
[9]. There may also be changes in the parathyroid hor-
mone induced cAMP levels, and vitamin D induced pro-
duction of alkaline phosphatase and osteoclacin [7]. OA
osteoblasts produced more insulin-like growth factor-1
and urokinase than normal cells. Other changes in the
subchondral osteoblasts in OA may be altered produc-
tion of interleukin (IL)-6, IL-8, metalloproteases and
transforming growth factor (TGF)-β1. Increased Wnt
signaling in the subchondral bone can also contribute to
OA development [7]. It is reminded that there is a close
cross-talk between the various tissues in the osteochon-
dral unit and hence changes in the subchondral bone
may affect the cartilage and the reverse may also occur.
The precise locale of the changes in OA within this unit
remains to be established. These changes may lead to
the development of bone cysts and lesions in the bone
marrow. Subsequently, the cartilage layer may be calfici-
fied and cracks may occur in it. The chondrocytes,
which are normally quiescent, may also actively prolifer-
ate and form clusters. An early-stage increase in the re-
modelling and bone loss followed by a slow remodelling
and subchondral densification are hallmarks of OA
pathogenesis [6].
OA affects the entire joint: the cartilage is damaged,
the underlying subchondral bone structure is remod-
elled, and a chronic inflammation of the synovium de-
velops [4]. There is sufficient evidence that during OA
the cross-talk between different tissues in the joint be-
comes more pronounced [3, 7, 8].
A current thinking is that OA is a chronic inflamma-
tion disease that occurs with gradual changes in the im-
mune system. This hypothesis has been presented in
detail in a recent review [5]. The progression of OA in-
volves changes in the production and functioning of
various cytokines. The cytokines involved may be in-
flammatory interleukins (IL-1β, IL-6, IL-15, IL-17, and
IL-18) and tumour necrosis factor-alpha (TNF-α) or
anti-inflammatory interleukins (IL-4, IL-10,and IL-13).
The increase in IL-1 causes damage to the articular car-
tilage [5]. The effect of TNF-α is similar to and synergis-
tic with the actions of IL-1β. The net result is a blockage
of the synthesis of proteoglycan components, the pro-
teins which bind proteoglycans, and type II collagen in
chondrocytes [10, 11]. Activated chondrocytes also pro-
duce the matrix metalloproteases MMP-1, MMP-
3,MMP-13 [5]. The effect of IL-6 on the cartilage is
similar to and in synergy with that of the other inflam-
matory cytokines and leads to a decrease in the synthesis
of type II collagen and an increase in the matrix metallo-
protease activity [5, 12]. Serum concentrations of IL-5
have been associated with the severity of pain in OA
[13]. However, the concentrations in the synovial fluid
are higher in early knee OA patients when compared to
end-stage OA [14]. The level of IL-17 increases in the
serum and in the synovial fluid. This level in the latter
correlates positively with the radiographic image of le-
sions in OA [15]. IL-18 affects chondrocytes and
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synovial cells by increasing the levels of several inflam-
matory compounds [5]. The anti-inflammatory cytokines
act primarily by decreasing the levels of inflammatory
cytokines, especially IL-1β and TNF-α [5]. Thus, there is
sufficient evidence to support the immune hypothesis in
OA.
Diagnosis of knee OA
Assessment of efficacy of a therapy requires an under-
standing of diagnosis of a disease such as OA which is
first reported by the patient as pain and inability to per-
form certain routine physical tasks. The clinician diag-
noses it as OA by ruling out other causes such as
rheumatoid, psoriatic and septic arthritis, injury and
other causes.
The diagnosis of the severity of OA is subjective: based
on a quality of life questionnaire, physical examination
and radiography (for a summary see [4]). The most com-
monly used quality of life measure is Western Ontario
McMaster Index (WOMAC) although other similar
measures such as visual analog scale (VAS) for pain and
Lequesne index are also used [16, 17]. An example of
the WOMAC questionnaire for the knee is at http://
www.orthopaedicscore.com/scorepages/knee_injury_os-
teopaedic_outcome_score_womac.html. The WOMAC
questionnaire contains several parts and contains ques-
tions related to severity and frequency of symptoms such
as swelling of the joint, grinding and clicking noises,
knee catching or hanging up, and the ability to
straighten or bend knees, pain in the knees in different
positions, knee functions and ability to perform daily
functions. Based on the sum of all the scores, the overall
WOMAC score is determined. Higher scores indicate
greater severity.
The physical exam focuses on the range of motion
(both passive and active), muscle strength, ligament sta-
bility and tenderness of the affected joints [4]. Any swell-
ing due to inflammation is also examined. Examination
by palpation of the OA knee may show the presence of a
crepitus (a crackling or crunching sensation on range of
motion of the joint).
Diagnosis of OA by imaging techniques has recently
been summarised [18]. Traditionally it has been diag-
nosed with X-ray radiographs from different angles to
look for joint space width (JSW) and asymmetry, and for
the presence of osteophytes. Grading schemes to de-
scribe the severity of the disease based on radiography
have been developed but these are questioned by others
since this method does not yield much information on
changes in soft tissue and cartilage [19]. Therefore, the
more recent methods such as magnetic resonance im-
aging (MRI), ultrasound, and optical coherence tomog-
raphy, have enhanced the OA diagnosis [18]. However,
most clinical trials have not used these methods due to
their high cost, low availability and the unavailability of
literature establishing their association with other cri-
teria of osteoarthritis. In most trials the assessment of
pain and function has been used.
Current therapies for management of knee OA
There are a large number of treatments of varying effi-
cacy and faith for OA. The non-pharmacological treat-
ments include education, exercise, physiotherapy, weight
loss, physical aids (supports, braces and walkers) and
surgical joint replacements [16, 20–24]. Massage with
and without pharmacological agents may also be benefi-
cial. Vitamins and herbs have also been used. A number
of recommendations on the treatments for OA made by
the American Academy of Orthopaedic Surgeons
(AAOS) are available at the website http://www.aao-
s.org/Research/guidelines/GuidelineOAKnee.asp.
Physical aids may enable the mobility of the patients
and allow them to carry out more physical activity.
Thus, even then the aim remains an increased physical
activity through some form of exercise. Weight loss is
the common mantra of the health care professionals for
the management of OA, it is moderately recommended
by AAOS but its validity may be questionable [25]. A
variety of exercise programs of varying effectiveness are
available for knee arthritis. It appears that for OA pa-
tients, exercises involving supervised slow movements or
isometric exercises may be efficacious and also have a
lower possibility of damage to the joint than other exer-
cises [16, 20–23, 26]. Therefore, aquatic exercises, yoga
and tai chi should be preferred. This is one of the stron-
gest recommendations from the AAOS. Running on
treadmills should be avoided. For less severe OA some
exercises with slower movements and greater resistance
may be added. Since the type, intensity and dose of exer-
cise may benefit each patient differently, physiotherapy
is often used to determine the type and extent of the ex-
ercises [23]. It is claimed that primary care physiothera-
pists and pharmacists may improve short term outcomes
for older adults with knee pain and reduce the use of
NSAIDs [26]. A long term randomised trial which will
monitor the effectiveness of community therapy and en-
hanced pharmacy review for people over the age of 55
has been initiated [20]. It may better resolve these
claims.
Several pharmacological agents have been used for
management of OA. Temporary pain relief and hence
improvement in function may be obtained with analge-
sics but this is not specific to OA. NSAIDs are used or-
ally and topically because they have some anti-
inflammatory and analgesic effects. They are also
strongly recommended by AAOS. However, they may
have severe adverse effects upon prolonged use. These
issues have been discussed in recent reviews and will not
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be retraced here [27, 28]. There are several commercial
preparations such Instaflex, Sierrasil, hyaluronic acid
and Aquamin of limited proven usefulness [29–31].
However, the combination of glucosamine and chondro-
itin sulfate is the most promising. This treatment may
be efficacious for pain relief, functional improvement
and also result in less joint space narrowing [32–36].
Herbs have been used for such treatment since ancient
times in Indian medicine (Ayurvedic) and Chinese medi-
cine [37, 38]. The use of some herbs is also mentioned
in the Bible (http://www.threemagi.com/frankincen-
se.html). Most of these herbs have antioxidant proper-
ties: they contain compounds or chemicals that can
modulate oxidative metabolism which is altered during
OA. Many in vitro studies are available in this area.
However, the human body is more complex than the
cells cultured in defined growth media. Oxidative stress
may play a role in several diseases but the benefits of dif-
ferent antioxidant supplements may be unique to each
one. We recently reviewed the literature on the benefits
of antioxidants in vision health and in obesity-diabetes II
[39, 40]. In vision health, the antioxidant supplements
containing vitamin C, vitamin E, lutein, zeaxanthin, zinc
and copper have a reasonable probability of retarding
age-related macular degeneration but the benefits in
other eye diseases are questionable. In obesity and dia-
betes 2, there are marginal benefits of supplementation
with zinc, lipoic acid, carnitine, cinnamon, green tea,
and possibly vitamin C plus E. Some of the antioxidants
are beneficial for obesity and others are better for glu-
cose level regulation.
Antioxidant supplements in knee OA
Reactive oxygen species in OA
A free radical is a molecule with an unpaired electron in
its outermost orbit [41, 42]. In biological systems, a free
radical that involves oxygen is termed a reactive oxygen
species (ROS) but the term ROS is used loosely for oxi-
dants such as peroxides. Normal physiological processes
result in the generation of ROS such as peroxide, super-
oxide, hydroxyl radical and peroxynitrite [41, 42]. Thus,
ROS occur normally in the body at very low concentra-
tions (nanomolar to micromolar). They are a necessary
evil since our body needs them for survival but, when in
excess, they may have deleterious effects. Our body gets
rid of the excess ROS using natural antioxidants such as
vitamin C (ascorbate), vitamin E, glutathione and various
enzymes [41–43]. The term oxidative stress is used as a
measure of the overall ROS status. It is the ratio of the
amount of peroxide present to that of the antioxidant
capacity of the cell. High levels of oxidative stress may
damage the cells by oxidising lipids and by altering DNA
and protein structure.
The concentrations of different ROS, reduced and oxi-
dised thiols, oxidative stress index and the related en-
zymes have been monitored in OA. In one study, the
serum thiol levels and catalase activity were lower in ad-
vanced stage OA patients than in controls and the oxi-
dative stress index was also higher (P <0.001, for all)
[44] (Fig. 1). In this work the levels of prolidase (a cyto-
solic exopeptidase which cleaves imidodipeptides and
imidotripeptides with C-terminal proline or hydroxypro-
line) activity correlated negatively with the oxidative
stress index. Another study examined the synovial fluid
from OA patients undergoing total knee replacement
surgery [45]. In these patients, the lipid peroxidation and
antioxidants were similar to those with the injured knee
joint patients but Vitamin E deficiency was associated
with OA [45]. However, a similar study found that the
extracellular superoxide dismutase (SOD) levels were
lower in the advanced stage OA patients than with the
knee injury controls [46]. There was also decline in the
concentrations of reduced glutathione and ascorbate
[46].
The above paradigm of oxidative stress is too simplistic
The kinetic constraints indicate that in vivo scavenging
of ROS is ineffective as an antioxidant defense [43, 47].
The concept does not consider that the damage may be
unique to each ROS in different cell types. Also, often
individual ROS species may act as signals. Therefore, a
better concept of oxidative stress is that of a disruption
of redox signalling and control [48]. In discussing knee
OA, this would be the effects on synovium, cartilage and
the joints. These effects relate directly to the OA patho-
physiology. For example, IL-1β is one of the most active
cytokines during the development of OA and it stimu-
lates the production of ROS such as peroxides and hy-
droxylated radicals and the production of NO and a
deficiency in SOD. The deficiency in SOD leads to
higher levels of superoxide. NO and superoxide react to
form peroxynitrite [46] (Fig. 1). Peroxynitrite can cause
telomere erosion by targeting guanine repeats in the
DNA. The net result is a decrease in the synthesis of col-
lagen II which is required for the maintenance of the
cartilage. Another potential pathway by which ROS can
damage the joint is through lipid peroxidation which
produces 4-hydroxynonenal. Higher levels of 4-
hydroxynonenal are present in the synovial cells of OA
compared to those of the healthy subjects [49]. In cartil-
age explants, 4-hydroxynonenal induced cleavage of col-
lagen II [49]. In chondrocytes isolated from OA patients,
4-hydroxynonenal inhibited the expression of collagen II
and increased the levels of factors which can cause its deg-
radation [49]. Thus, the production of 4-hydroxynonenal
by ROS could play a major role in OA (Fig. 1). It is
reminded that the joint is a system in which the cartilage,
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the bone, the ligaments and the synovium form a capsule
and there is sufficient cross-talk between all the tissues. A
diffusion of ROS and lipid peroxidation products may
occur between them. Thus, the damage to one element of
the joint may influence others through fluid diffusion and
by paracrine factors [50].
Antioxidant supplements and OA
The role of ROS in the pathophysiology of knee OA pro-
vides for the rationale that suppressing the ROS levels
with the appropriate antioxidant supplements may retard
the progress of the disease. What remains to be discussed
is the reality of the observations on the effects of such
supplements on prevention and/or management of OA.
The effects of food intake and various vitamins and re-
lated compounds on OA has been examined and
reviewed [51–59]. One concludes that nutritional habits
involving fruits, fruit juices and vitamin supplements
may be beneficial in the long run but they may not help
once OA has already been initiated. Several antioxidant
supplements derived from turmeric, avocado, Boswellia
and other herbs will be discussed.
Turmeric
Turmeric is used extensively as a spice and has been
used for over 4000 years as an Ayurvedic medicine. It is
the rhizome of Curcuma longa (some studies use Cur-
cuma domestica) and contains over 20 different active
compounds [60]. Curcumin, a compound with antioxi-
dant properties, was isolated from turmeric about
200 years ago [61]. The properties of curcumin and its
potential role in the therapy of several chronic diseases
including arthritis, cancer and neuronal disorders have
been explored. The rationale for its use in OA comes
from several in vitro studies. Curcumin inhibited the
matrix degradation of articular explants and chondro-
cytes [51]. It decreased the production of MMP-3, −9
and −13 via c-Jun-N-terminal kinases, nuclear factor
Fig. 1 Role of oxidative stress in cartilage damage during OA. OA is hypothesised as a chronic inflammation disease that occurs with gradual
changes in the immune system (see Pathophysiology of knee OA). IL-1β and TNF-α and other inflammatory factors increase in OA. This pathway
leads to induction of NO synthase, production of larger amounts of NO and a deficiency in SOD and catalase (see Role of ROS in OA). The defi-
ciency in SOD leads to higher levels of superoxide which combines with NO to produce peroxynitrite which can cause telomere erosion by tar-
geting guanine repeats in their DNA telomeres. The net result is a decrease in the synthesis of collagen II. The decrease in catalase results in
accumulation of peroxide to increase lipid peroxidation which produces 4-hydroxynonenal. The 4-hydroxynonenal increases factors which break-
down collagen II and also inhibits the expression of collagen II. The net result is the cartilage damage that occurs in OA. Note that the scheme
shown here is only a summary
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kappa-beta (NFκβ), and the JAK/STAT pathways. It also
restored type II collagen and glycosaminoglycan synthe-
sis. A random double blind study on knee OA patients
compared the ability of curcuminoids and the NSAID
diclofenac to inhibit cyclo-oxygenase 2 [62]. Both the
groups significantly reduced (p <0.001) cyclo-oxygenase
2 secretions by similar efficacies.
A PubMed search in August 2015 with the words
“tumeric/curcumin” and “osteoarthritis” and “knee”
showed 21 entries of which 11 were clinical trials involv-
ing pain and function with different diagnostic measure-
ments, durations, controls, blindness and conflicts of
interests (Table 1). All the trials showed benefits of cur-
cumin except for one in which significance levels were
not attained due to a large variance. Some studies have
also compared their effects with those of NSAIDs. One
randomised double blind study compared the effects of
ibuprofen (2 × 400 mg/day) with those of curcumin (4 ×
500 mg/day) in patients who were over 50 years of age,
had severe knee pain and their radiography showed the
presence of osteophytes [63]. Both the groups showed
improvements in all assessments but the curcumin
group was statistically better in patient satisfaction,
timed walk or stair climbing and pain during walking or
stair climbing. A similar study with a larger number of
patients compared the effects of C. domestica extracts
(1500 mg/day, n = 171) with ibuprofen (1200 mg/day n
= 160) for 4 weeks [64]. After 4 weeks, all measures of
WOMAC and the 6 min walk test improved significantly
(p <0.001) in both groups with no differences between
the groups. The safety profile was found to be somewhat
better in the curcumin group. Another study compared
the effects of the NSAID diclofenac (75 mg) combined
with placebo (n = 36) or with Curcuma longa extracts
(1000 mg) (n = 37) on pain and function. The combin-
ation was no more effective than diclofenac alone indi-
cating that the effects of the two treatments are not
additive (Table 1) [65].
A major criticism is that most studies did not report
curcumin levels in the patients. This is important be-
cause curcumin absorption has been reported to be ex-
tremely poor when it is used alone [66–69]. To further
complicate matters, one study reports that even a curcu-
minoid free polysaccharide rich extract (NR-INF-02) of
Curcuma longa may be efficacious against OA (Table 1)
[70].
There have been several attempts to improve the bio-
availability of curcumin. One study examined the effects
of Meriva (curcumin plus phosphatidylcholine for better
bioavailability) (Table 1) [71]. Patients (n = 100) with
mild OA were recruited. They were already under vari-
ous treatments. The control group continued with only
the current treatment but Meriva (2 × 500 mg/day-total-
ling 200 mg curcumin) was added to the study group.
After 8 months, the control group showed an improve-
ment on the WOMAC scale but the treatment group
performed much better. The mean treadmill test dis-
tances changed from 82.3 to 156 m/6 min in the control
group but the increase was much greater in the treat-
ment group (from 77.3 to 344 m/6 min). All the inflam-
matory markers (IL6, IL1β, sVCAM-1, sCD40L, ESR)
were significantly decreased (p <0.05) in the study group
but not in the control group. Another study reported
the effects of Meriva and glucosamine (n = 63) vs chon-
droitin and glucosamine (n = 61) in patients with mild
OA [66]. The patients improved more with Meriva plus
glucosamine than with chondroitin plus glucosamine in
WOMAC scores and in the treadmill test. No adverse
effects were reported. However, this was not a rando-
mised blind study. It is pointed out that the levels of cur-
cumin in the patients were not reported in either study
using Meriva [66, 71]. Another study mixed curcumin
with polysorbate for better bioavailability [67]. Curcumin
(42 mg/capsule, 2 × 3/day) was given for 3 months. The
treatment decreased collagen II but had no significant
effects on pain or other biomarkers measured. In an-
other multicenter larger study this combination was also
beneficial for pain and flexibility [72]. However, curcu-
min levels in the patients were not reported in either
study. An intravenous infusion of high concentrations of
liposomes containing curcumin altered the shape of
erythrocytes [73].
One study determined the effect of piperine (inhibits
hepatic and intestinal glucuronidation) on the bioavail-
ability of curcumin [69]. After a dose of 2 g curcumin
alone, the curcumin levels in the serum were near
or below the detection limit. In contrast, a co-
administration of 20 mg piperine increased the bioavail-
ability by 20-fold (p <0.01). It was concluded that piper-
ine enhanced the serum concentration, extent of
absorption and bioavailability of curcumin with no ad-
verse effects. A pilot random double blind study with
53 patients was conducted on the effects of curcumin
plus bioperine (3 × (300 mg curcumin + 5 mg piper-
ine)/day) or a placebo for 6 weeks (Table 1) [68]. The
treatment led to significant improvements in pain re-
lief and function compared to the placebo. However,
there are three concerns with this study. There was no
control group without piperine, curcumin levels were
not determined, and there was no control group with
piperine alone. Therefore, the results are difficult to
interpret. An in vitro study on chondrocytes from an
OA patient showed that piperine alone can abrogate
the IL1-beta-induced overexpression of inflammatory
mediators [74].
Curcumin has been reconstituted with non-
curcuminoid components of turmeric into a proprietary
preparation termed BCM-95CG or Biocurcumax [75].
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Table 1 Knee OA antioxidant supplements based on turmeric, avocado and Boswellia
Reference Study type Parameters measured results Comments
Turmeric (curcumin)
Kuptniratsaikul
et al. 2014 [63,
64]
RDBa: compared curcumin (n = 171)
with ibuprofen (n = 160)
Thai modified WOMAC, 6 min walk
and patient satisfaction
All improved in both groups (p <.001) with no intergroup
differences
Trial only 4 weeks
Safety profile better for curcumin
Belcaro et al.
2010 [71]
Open: best available treatment +
Meriva versus best available treatment
(n = 100)
Treadmill walking test, WOMAC and
Karnofsky, and oxidative stress levels,
inflammatory markers.
8 months - all measures improved with Meriva (p <0.05) Not a blind study
Belcaro et al.
in 2014 [66]
Open: Meriva and glucosamine (n =
63) vs chondroitin and glucosamine
(n = 61)
Treadmill walking test, WOMAC and
Karnofsky scales
4 month - similar improvements in both groups. Use of
NSAIDS decreased in both groups
Not a blind study
Panahi et al. in
2014 [66, 68]
RDBP: curcumin + bioperine (n = 21) vs
placebo (n =19)
WOMAC, VAS, Lequesne’s pain and
stiffness score
6 weeks - improvement in WOMAC, VAS, Lequesne’s pain
scores (p <.0010) but not in stiffness score




DB: (Curcumin 1000 mg + diclofenac
75 mg)/day (n = 44) vs (diclofenac
75 mg + placebo) (n = 44)
VAS AND Knee Injury and
Osteoarthritis Outcome Score
No difference between groups for pain and function. Small group size, submaximal doses The
effects of two treatments is not additive
Henrotin, Y et
al. 2014 [67]
Open: Flexofytol (curcumin with
polysorbate) (n = 100) in real life
situations
Serum Coll-2-1, Coll-2-INO2, Fib3-1,
Fib3-2, CRP, MPO, CTX-II. VAS pain
6 months - Coll-2-1 decreased. No change in pain Not a blind study, no control
Appelboom et
al. 2014 [72]
Open: Flexofytol- physicians in real life
situation (n = 820)
Pain severity, flexibility and quality of
life
6 months - improved in all (p <.0001), use of other
treatments decreased (p <.0001)
Not a blind study




RDB: C. domestica 3 × 30 mg (n = 34)
vs diclofenac 3 × 25 mg (n = 39)
COX 2 levels in sinovial fluid at time =
0 and at 4 weeks




RSBP: NR-INF-02 1 g vs glucosamine
1.5 g vs NR-INF-02 + glucosamine vs
placebo
VAS and WOMAC 6 weeks - all treatments showed significant improvement
over baseline and placebo
Small study (<30/ group) and over short
time period. NR-INF-02 is curcuminoid




RDBP: ASU (n = 83) vs placebo (n = 80) Lequesne’s, Initially all groups received
NSAID
6 months - Lequesne’s improved and NSAID use
decreased
Over time pain similar in both groups
Maheu et al.
1998 [81]
RDBP: piascledine 300 mg (n = 85) vs
placebo (n = 79) (knee and hip OA)
Lequesne’s, VAS for pain, and NSAID
usage
6 months + 2 month follow up. Decrease in Lequesne’s (p
<0.001), pain (p <0.003) and NSAID usage.
Improvement more marked in hip OA.
Lequesne et al.
2002 [95]
RBDP: piascledine 300 mg (n = 55) vs
placebo (n = 53)
JSW, VAS pain, global assessment 2 years - no statistical difference in JSW or clinical
parameters.
Posthoc analysis - when OA was severe,
ASU slowed the disease progression
Pavelka et al.
2010 [96]
RDB: piascledine 300 mg vs
chondroitin 1200 mg (n = 263)
WOMAC, Lequesne’s, VAS, global
assessment, use of rescue medication
6 months + 2 month follow up. All parameters improved
during treatment. Stabilized or improved in the follow up.
No differences between groups.




RDBP: piascledine 300 mg (n = 345) JSW, WOMAC, Lequesne’s 3 years - fewer progressors in the ASU group. No

















RDB crossover: Boswellia serrata extract
vs placebo (n = 30)
Knee pain, inflection, walking distance,
frequency of swelling, radiology
8 weeks - 3 weeks washout 8 weeks crossover. Significant




RDBP: 5-Loxin (B. serrata extract
enriched with 30 % AKBA) (n = 75)
Pain and function VAS, WOMAC and
Lequesne’s
90 days - improvement in stiffness, function and pain
scores, decreased MMP-3 (p <0.0001).
Serum biochemistry also improved,
bioavailability of AKBA is low
Sengupta et al.
2010 [86]
RDBP: Aflapin 100 mg vs 5-Loxin
100 mg vs placebo (n = 20/group)
WOMAC, Lequesne’s, VAS, and serum
biochemical, hematological and urine
changes
90 days - improvement in pain and physical function in
both treatment groups.
Small study over short time. Aflapin
inhibits MMP-3 and ICAM-1
Gupta et al.
2011 [98]
Open: Shallaki tablet (6 g/d) or tablet
and ointment together (n = 56 total)
Pain, stiffness and swelling, mental
state (Jung scales). Radiology,
hematology and biochemistry
2 months - both groups reported significant
improvements in pain, stiffness and swelling and by
radiology
Not a blind study. No control group.




RDBP: Alfapin vs placebo (n = 30/
group)
WOMAC, Lequesne’s and VAS for pain
and serum biochemical,
hematological and urine changes
30 days - significant improvement in pain and function
but not in biochemistry




RDBP crossover: Articulin-F capsule (W.
somnifera, B. serrata C. longa Zinc com-
plex) (n = 42)
Pain, stiffness, grip strength, Ritchie
articular index, disability score,
radiology.
3 months 2 weeks washout crossover 3 months - pain and




RDBP: RA-11 (W. somnifera, B. serrata,
Z. officinale, and C. longa) vs placebo
(n = 90)
WOMAC, VAS and hematological,
urine and biochemical tests
32 week - WOMAC, VAS improved over placebo Very high dropout rate
Chopra et al.
2013 [89, 100]
RDBP: Glucosamine vs celecoxib vs
SGCGc vs SGC (n = 440)
Weight bearing pain modified
WOMAC
24 weeks - improvement in pain and function in all
groups. For WOMAC pain, SGCG worked marginally better
than SGC.
Some patients had adverse hepatic
effects of SGCG and SGC.
aThe trials types were random single blind (RSB), random double blind with or without placebo (RDBP, RDB) or open
bStudies supported by Laboratoires Expanscience, Courbevoie, France)
cSGCG capsule (400 mg) contained Zingiber officinale, Tinospora cordifolia, Phyllanthus emblica and B. serrata. The SGC capsule (400 mg) was similar to SGCG (both for content and quantity) except for the absence of B.













Biocurcumax increased the oral bioavailability of curcu-
min when compared to curcumin alone or curcumin
plus lecithin. However, there are no reports using this
preparation for OA.
Studies on the management of knee OA have also
been conducted using Curcuma extracts in combination
with other substances (Table 1). One trial used the com-
bination of roots of Withania somnifera, the stem of
Boswellia serrata and rhizomes of Curcuma longa and a
zinc complex. There was a significant improvement in
pain relief and function [76]. Ainat - a preparation con-
taining devil’s claw, turmeric and bromelain also showed
a clinically relevant improvement in acute and chronic
pain [77].
Avocado-soya extract
Avocado and soybean oils are used for manufacturing
soap and the unsaponifiable fraction from these oils is
termed avocado/soybean unsaponifiable (ASU). ASU has
been tested in the management of OA. ASU contains
phytosterols, β-sitosterol, campesterol, and stigmasterol,
fat soluble vitamins, triterpene fatty acids and possibly
furan fatty acids, but the identity of the active compo-
nents in it is unknown [78]. Several formulations of
ASU are available on the market as supplements. Pia-
scledine, which contains the unsaponifiables as one part
from avocado and two from soybean, is a unique pat-
ented preparation [79]. In articular chondrocyte cultures
ASU may modulate NFκβ levels to inhibit inflammatory
cytokines and stimulate collagen synthesis [78]. Animal
studies also support its benefits in OA.
A PubMed search in August 2015 with the words “av-
ocado/ASU” and “osteoarthritis” and “knee” showed 25
entries of which five were human clinical trials on pain
and function of OA in hip and knee (Table 1) . Litera-
ture on the human trials of ASU in hip and knee OA,
and for the rationale of this therapy has been reviewed
recently [78]. It is pointed out that there may be a con-
flict of interest in these studies. Also, one should con-
sider that soybean protein alone may be beneficial for
OA and this complicates the interpretation of the bene-
fits of ASU [80].
The effect of ASU on patients with hip (n = 50) or
knee (n = 114) OA was examined in a randomised,
double blind, placebo controlled, multicenter trial with a
6 month treatment period (Table 1) [81]. After the
6 months its efficacy was greater than that of the pla-
cebo (P <0.001 for intergroup difference at month 6).
The decrease in the Lequesne index (from 9.7 ± 0.3 to
6.8 ± 0.4) was significantly greater in the ASU group
than in the placebo group (from 9.4 ± 0.3 to 8.9 ± 0.4).
Fewer patients treated with ASU required NSAIDs
(48 %) than those in the placebo group (63 %) (p =
0.054). The improvements appeared to be more marked
in patients with hip than those with knee OA. Another
similar study confirmed these findings [82]. In yet an-
other study, the effects of two doses (300 or 600 mg
daily) of ASU were compared in patients with knee OA
over 3 months (Table 1) [83]. Both doses were effective.
At day 90, NSAIDs and analgesics intake decreased to
less than half in 71 % patients receiving ASU (300 mg
or 600 mg) compared to 36 % in the placebo group
(p <0.01). The Lequesne’s index dropped by 3.9, 2.9 and
1.9 points with 600 mg ASU, 300 mg ASU and placebo,
respectively (p <0.01).
Boswellia
Resins from trees of Boswellia serrata, and other species
of this genus, have been used for arthritis and other dis-
eases in Ayurvedic medicine since ancient times in India
where it is termed shallaki or salai (http://en.wikipe-
dia.org/wiki/Boswellia_serrata). In Europe, it is known as
olibanum or Frankincense which is mentioned several
times in the Bible (http://www.threemagi.com/frankin-
cense.html). Boswellia resins contain several different
boswellic acids such as beta-boswellic acid, keto-beta-
boswellic acid, and acetyl-keto-beta-boswellic acid (AKBA).
AKBA is an inhibitor of the lipoxygenase pathway and is
suggested to have anti-inflammatory properties [84].
A PubMed search in August 2015 with the words
“Boswellia/shallaki/salai/AKBA” and “osteoarthritis” and
“knee” showed 18 entries of which only nine were clin-
ical trials, on Boswellia alone or in combination with
other substances, with different diagnostic measure-
ments, durations, controls, blindness and conflicts of in-
terests. This included several proprietary preparations
from Boswellia extracts (Table 1). Most studies exam-
ined mainly pain relief or improvements in function.
The Boswellia extract preparations aflapin and 5-loxin
were both shown to be beneficial in arthritis although
the studies used small numbers of patients, were con-
ducted over short periods only, and did not meet all
rigorous criteria [85–88]. Nevertheless, almost all the
studies have shown some benefit for OA (Table 1). In
some studies, preparations combinations of Boswellia
and several other substances were used (Table 1). A
small random double blind crossover study conducted in
1991 found that articulin (combination of W. somnifera
450 mg, B. serrata 100 mg, C. longa 50 mg, Zinc com-
plex 50 mg) improved pain and functional symptoms of
OA (Table 1) [76]. However, a literature search showed
that the study was not repeated with a larger size. A
more extensive study compared two drugs termed
SGCG and SGC, both containing several herbs but only
SGCG containing Boswellia (Table 1) [89]. Both drugs
were effective against OA symptoms but the drug con-
taining Boswellia was marginally more effective in redu-
cing the WOMAC pain symptoms.
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Ayurvedic and Chinese medicines
Several herbal products containing antioxidants are used
in Ayurvedic medicine. For example, roots of Withania
somniferum are used to prepare ashwagandha. It con-
tains withanaloids, most importantly withaferin A [90].
Tinospora cordifolia (Guduchi) is considered a divine
herb and it contains diterpenoids termed tinosporides
[91]. Emblica officinalis (or Phyllanthus emblica) is
termed amla or amlaki and is rich in vitamin C and
emblicanins A and B [92]. Zingiber officinale (Ginger)
root is not only used extensively in cooking but also has
several medicinal antioxidants. The analysis of volatile
oils of fresh and dried ginger showed camphene, p-cine-
ole, α-terpineol, zingiberene and pentadecanoic acid as
major components [93]. There are several studies dem-
onstrating the usefulness of these antioxidants in OA. A
major complication in comparing their usefulness comes
from a lack of an exact parallelism between the patho-
logical classifications in Ayurvedic system versus the
Western system of medicine. Further, several studies
have used only small populations, have fewer controls
and their methods of analysis may lend to bias. The
characteristics of the studies are presented in a recent
review along with their risk of bias according to
Cochrane risk of bias tool [38]. Their study included 19
randomized and 14 non-randomized controlled trials on
12 different drugs and three non-pharmaceutical inter-
ventions. They concluded that “The drugs Rumalaya and
Shunti-Guduchi seem to be safe and effective drugs for
treatment of OA-patients, based on these data. However,
several limitations relate to clinical research on Ayur-
veda. Well-planned, well-conducted and well-published
trials are warranted to improve the evidence for Ayur-
vedic interventions.” However, part of the problem is
that these are very complex proprietary preparations
with undisclosed exact compositions. For example,
Rumalaya contains Mahayograj guggul, Shankha bha-
sama, purified Shilajeet, Swarnamakshik bhasama, Lata-
kasthuri and Shallaki, Jaya galangal, Licorice and
Tinospora Gulancha. Chemical compositions of each of
these is not exactly known.
Chinese herbal medicines have been used for treating
OA in China for centuries. The most commonly pre-
scribed OA medicines in Taiwan are Du-huo-ji-sheng-
tang plus Shen-tong-zhu-yu-tang, and the triple-drug
combination was Du-huo-ji-sheng-tang, Gu-sui-pu (Dry-
naria fortune (Kunze) J. Sm.), and Xu-Duan (Himalaya
teasel) [37]. These are all polyplant preparations which
have not been critically evaluated as per today’s criteria.
One study examined the preparation Duhuo Jisheng
Tang for treating OA of the knee [94]. This preparation
contains parts from 15 different herbs and its chemical
constituents include coumarins, phytosterols, polysac-
charides, flavanoids, monoterpene glycoside, galloyl
glucoses, saponins, ginsenosides and alkaloids. Patients
(n =68) of both genders and 59.2 ± 10.2 years of age
were given a dose 2.5 g twice daily for 4 weeks. There
was a highly significant improvement in the WOMAC
scores (pain, stiffness and function) and in visual analog
scale for pain. As noted, the study used a small number
of subjects for a short duration and there was no pla-
cebo group.
Synopsis
OA is a disease of inflammation of large articulate joints
with the tibiofemoral joint inflammation being more
prevalent. There is no known cure for this disease but
considerable progress has been made in joint replace-
ment surgery. The pharmacological strategies for coping
with OA include glucosamine plus chondroitin sulfate,
hyaluronic acid or corticosteroid injections and NSAIDs.
The pathophysiology of OA is consistent with the hy-
pothesis that the inflammatory molecules and ROS in-
crease with the onset of the disease. Therefore, it is
logical to think that antioxidant supplements may be of
some benefit. Curcumin which is isolated from Curcuma
longa may be efficacious for pain relief and function re-
tention in OA patients. Several products which increase
oral bioavailability of curcumin may be promising. An-
other beneficial product may be ASU. Boswellia resins
may also be beneficial and proprietary preparations de-
rived from it and containing AKBA may also have good
efficacy. All of these products have fewer adverse effects
than the chronic use of NSAIDs. Ayurvedic and ancient
Chinese medicines may also be beneficial.
Critical appraisal
The problem of defining OA has been elegantly dis-
cussed in a Clinical Viewpoint [2]. Common under-
standing today is that OA is a sequential process: loss of
proteoglycans on the cartilage surface, death of chondro-
cytes in deeper layers, hypertrophy and aggregation of
remaining chondrocytes, formation of surface cracks
parallel to articular face, flow of synovial fluids into these
defects, immune reactions due to cartilage fractures,
penetration of synovial fluid into defects and cyst forma-
tion, osteophyte formation leading to joint crepitus and
stiffness, restriction of movements and narrowing of
intra-articular space. Pain severity increases with the
various stages. One of the problems is that radiographic
imaging may show joint space narrowing without any
loss in range in motion or any other symptoms. Radio-
graphic imaging does not show cartilage damage and
hence MRI, ultrasound, and optical coherence tomog-
raphy have been introduced recently for diagnosis. How-
ever, most studies in drug trials restrict to methods such
as WOMAC, VAS or Lequesne index using question-
naires or walking or stair climbing. Each of these indices
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contains a large number of items which deter from a
focus on the definition of the disease. With the excep-
tion of quantitative measures such as distance walked in
6 min, the methods are highly subjective and a source of
bias due to their subjectivity. Stair climbing is a good
functional measure but it may often depend on cardiore-
spiratory abilities in addition to osteoarthritis.
A major hurdle in today’s evidence based medicine is
money. When money is to be made such as in propri-
etary or patented drugs, a large investment is expected
in the trials. However, when a traditional supplement is
to be tested, financial investments may be small and
hence large trials do not occur. Conflicts of interest - de-
clared or undeclared may also come about due to such
investments. For example, turmeric has been used in
Ayurvedic and Chinese medicine for arthritis since an-
cient times. Curcumin was isolated from it in 1815 [61].
Curcumin has been tested extensively for its benefits in
arthritis and other diseases. It is interesting that the bio-
availability of this compound is extremely low when
given orally in powdered forms in capsules. Yet, when
consumed in large doses, it is beneficial for OA. Com-
mercial proprietary preparations using curcumin have
been developed to increase its bioavailability. It is ironic
that one of the products is made from reconstituting
curcumin with curcumin free components from tur-
meric. Another interesting product contains curcumin
and piperine which can be isolated from black pepper. It
enhances the bioavailability of curcumin. These products
are being tested for their efficacies. The Indian house-
wife uses turmeric and black pepper routinely in cook-
ing. Yet, the efficacy of this product will not be tested
since there is nothing proprietary in it. Even if money
were available, taste and colour of turmeric and black
pepper would deter a randomized double blind clinical
study. Placebos would also be hard to find. This example
reflects the type of difficulty one has in evaluating the
usefulness of the literature in this area. These difficulties
often muddle the clarity and usefulness of the
conclusions.
Recommendations
This review shows that there is some evidence for bene-
fits of antioxidant supplements in pain relief and func-
tion in knee OA. These supplements with the most
evidence include curcumin, avocado-soya bean unsapo-
nifiables, Boswellia and several preparations used in
Ayurvedic and Chinese medicine. These should be tested
further and used, at least, to decrease the use of NSAIDs
which have more adverse effects.
Ancient medicine should be tested as such rather than
proprietary products made from them. It should be
assessed whether diet with turmeric and black pepper
results in sufficient levels of serum curcumin. Promotion
of dietary habits may be more economical and of longer
term benefit than the development of products made
from extracts used in ancient medicine.
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